These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 20884129)

  • 41. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
    Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
    Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study.
    Jorgo K; Polgar C; Major T; Stelczer G; Herein A; Pocza T; Gesztesi L; Agoston P
    Pathol Oncol Res; 2020 Apr; 26(2):905-912. PubMed ID: 30888646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
    Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
    Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
    Tandberg DJ; Oyekunle T; Lee WR; Wu Y; Salama JK; Koontz BF
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):396-405. PubMed ID: 29559284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome.
    Fonteyne V; Lumen N; Ost P; Van Praet C; Vandecasteele K; De Gersem Ir W; Villeirs G; De Neve W; Decaestecker K; De Meerleer G
    Radiother Oncol; 2013 Nov; 109(2):229-34. PubMed ID: 24016677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
    Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
    Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
    Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results.
    Valeriani M; Carnevale A; Osti MF; DE Sanctis V; Agolli L; Maurizi Enrici R
    Radiat Oncol; 2014 Sep; 9():214. PubMed ID: 25260377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.